Proteomics International Laboratories (ASX:PIQ) is a wholly owned subsidiary and trading name of PILL, a medical technology company at the forefront of predictive diagnostics and bioanalytical services. The Company specialises in the area of proteomics - the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) is pleased to announce the assignment of billing code (0579U) by the American Medical Association (AMA) for the next-generation of the PromarkerD test system.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) is pleased to announce a major $6 million expansion of the WA Proteomics Facility, in partnership with The University of Western Australia (UWA), the WA State Government and Bioplatforms Australia.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics, is pleased to announce that the Japan Patent Office has granted the Company its first patent for PromarkerEndo, the proprietary diagnostic blood test for endometriosis.
Proteomics International Laboratories Ltd (ASX:PIQ) Next-gen PromarkerD test system released for predicting DKD
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics, proudly announces the initial US launch of its groundbreaking predictive test for diabetic kidney disease, PromarkerD, at the 85th Scientific Sessions of the American Diabetes Association (ADA) in Chicago, Illinois.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics is pleased to announce the publication of clinical validation results in the journal Proteomes showing its PromarkerEso blood test can diagnose esophageal adenocarcinoma with high accuracy.
Proteomics International Laboratories Ltd (ASX:PIQ) has unveiled landmark clinical data confirming its Promarker(R)Endo blood test as a highly accurate, non-invasive diagnostic tool for endometriosis.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics, is pleased to announce another milestone in the development of its PromarkerEndo diagnostic test for endometriosis.
Proteomics International Laboratories Ltd ((ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics, is pleased to announce that its subsidiary OxiDx Pty Ltd, has secured new intellectual property protection following the grant of a patent in China for the platform technology which precisely measures levels of oxidative stress.
On 22 April 2025, Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) announced that it will be conducting a placement of 10,810,811 fully paid ordinary shares in the Company at an issue price of $0.37 per Share to sophisticated, institutional and professional investors, raising approximately $4 million.
Correction - Notice of Extraordinary General Meeting/Proxy
Notice of Extraordinary General Meeting/Proxy Form
Investor Presentation - JMM Biotech Forum
Interim Financial Report and Appendix 4D
Notice of Annual General Meeting/Proxy Form
